Boston Scientific claims win over Edwards Lifesciences in German TAVR spat
Boston Scientific (NYSE:BSX) today claimed a win in its global tussle with Edwards Lifesciences (NYSE:EW) over transcatheter aortic valve replacement patents.
It’s the latest development in a long-running battle being fought on multiple legal fronts over the companies’ respective TAVR patent portfolios. In March 2017, a German court issued a mixed decision in the spat, less than a week after a U.K. patent court handed down a similar decision.
A year later, the U.K. Court of Appeals upheld that ruling; across the pond that some month, Edwards won a round when the U.S. Patent & Trademark Office ruled in its favor. And last April, the European Patent Office revoked an Edwards patent.
The newest decision grants Boston Scientific’s bid for an injunction barring the Sapien 3 Ultra valve from the German market, after the District Court of Düsseldorf found that Edwards infringed a patent Boston acquired with the $435 million purchase of Swiss valve maker Symetis in May 2017. The infringement concerns the fabric used on the valve seal, Marlborough, Mass.-based Boston Scientific said.
But the issue is moot until the Sapien 3 Ultra wins CE Mark approval in the European Union, and even then Boston Scientific must put up a bond worth about $11.5 million (€10 million) to enforce the ruling, according to Edwards.
“We are pleased with the steady cadence of European court rulings which uphold and validate our TAVR intellectual property against compet...
Source: Mass Device - Category: Medical Devices Authors: Brad Perriello Tags: Featured Legal News Patent Infringement Replacement Heart Valves Boston Scientific Edwards Lifesciences Source Type: news
More News: Cardiology | Germany Health | Grants | Heart | Heart Valve Disease | Heart Valve Surgery | Heart Valves | Hospitals | Legislation | Study | Switzerland Health